Allogeneic responses were also ruled out as increased cancer killing is only observed in the presence of itolizumab and not in untreated or isotype control-treated PBMC. In addition, CD6 negative cells have shown reduced reactivity to allogeneic stimulation (31, 32). Here, CD6 is linked to cancer.